Prolonged versus short infusion rates for intravenous magnesium sulfate administration in hematopoietic cell transplant patients

Pam M. Ku, Jennifer L Waller, Claude Sportes, Amber B. Clemmons

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Hematopoietic cell transplant (HCT) recipients often require intravenous (IV) magnesium repletion due to poor dietary intake, gastrointestinal loss, and use of concomitant magnesium wasting medications. Prolonging the IV magnesium infusion rate has been postulated to reduce renal clearance and improve retention; however, limited evidence supports this hypothesis. Methods: We reviewed autologous and allogeneic HCT recipients (n = 82) who received IV magnesium at our institution between 2014 and 2016: 41 patients received IV magnesium at a prolonged rate of 0.5 g/h and 41 patients at > 0.5 g/h (mean 2.07 g/h). Primary outcome was percent of days in which magnesium levels were in desired therapeutic range (2–2.7 mg/dL) during hospitalization. Results: Baseline characteristics were similar between cohorts: no difference existed between groups in incidence of gastrointestinal graft-versus-host disease or the percentage of patients who received magnesium replacement in maintenance fluids, received concomitant oral magnesium supplementation, or received parenteral nutrition. Percent of days in desired therapeutic range was not different between groups (p = 0.3). No difference existed between groups with respect to total amount of IV magnesium repletion (22.5 vs. 21.4 g, p = 0.81) or number of days of IV replacement (7.2 vs. 6.2 days, p = 0.41). In terms of safety, there was no difference between groups with respect to incidence of hypomagnesemia or hypermagnesemia (p = 0.43 each). Conclusions: Overall, prolonging the infusion rate did not correlate with improved magnesium retention based on amount and frequency of magnesium repletion or attainment of goal levels in HCT patients.

Original languageEnglish (US)
Pages (from-to)2809-2814
Number of pages6
JournalSupportive Care in Cancer
Volume26
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Magnesium Sulfate
Intravenous Infusions
Magnesium
Transplants
Incidence
Parenteral Nutrition
Graft vs Host Disease
Hospitalization
Maintenance

Keywords

  • Administration
  • Hematopoietic cell transplantation
  • Intravenous
  • Magnesium
  • Rate

ASJC Scopus subject areas

  • Oncology

Cite this

Prolonged versus short infusion rates for intravenous magnesium sulfate administration in hematopoietic cell transplant patients. / Ku, Pam M.; Waller, Jennifer L; Sportes, Claude; Clemmons, Amber B.

In: Supportive Care in Cancer, Vol. 26, No. 8, 01.08.2018, p. 2809-2814.

Research output: Contribution to journalArticle

@article{2bf32b762c014f59bea461a7ade4aaa3,
title = "Prolonged versus short infusion rates for intravenous magnesium sulfate administration in hematopoietic cell transplant patients",
abstract = "Purpose: Hematopoietic cell transplant (HCT) recipients often require intravenous (IV) magnesium repletion due to poor dietary intake, gastrointestinal loss, and use of concomitant magnesium wasting medications. Prolonging the IV magnesium infusion rate has been postulated to reduce renal clearance and improve retention; however, limited evidence supports this hypothesis. Methods: We reviewed autologous and allogeneic HCT recipients (n = 82) who received IV magnesium at our institution between 2014 and 2016: 41 patients received IV magnesium at a prolonged rate of 0.5 g/h and 41 patients at > 0.5 g/h (mean 2.07 g/h). Primary outcome was percent of days in which magnesium levels were in desired therapeutic range (2–2.7 mg/dL) during hospitalization. Results: Baseline characteristics were similar between cohorts: no difference existed between groups in incidence of gastrointestinal graft-versus-host disease or the percentage of patients who received magnesium replacement in maintenance fluids, received concomitant oral magnesium supplementation, or received parenteral nutrition. Percent of days in desired therapeutic range was not different between groups (p = 0.3). No difference existed between groups with respect to total amount of IV magnesium repletion (22.5 vs. 21.4 g, p = 0.81) or number of days of IV replacement (7.2 vs. 6.2 days, p = 0.41). In terms of safety, there was no difference between groups with respect to incidence of hypomagnesemia or hypermagnesemia (p = 0.43 each). Conclusions: Overall, prolonging the infusion rate did not correlate with improved magnesium retention based on amount and frequency of magnesium repletion or attainment of goal levels in HCT patients.",
keywords = "Administration, Hematopoietic cell transplantation, Intravenous, Magnesium, Rate",
author = "Ku, {Pam M.} and Waller, {Jennifer L} and Claude Sportes and Clemmons, {Amber B.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s00520-018-4127-z",
language = "English (US)",
volume = "26",
pages = "2809--2814",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Prolonged versus short infusion rates for intravenous magnesium sulfate administration in hematopoietic cell transplant patients

AU - Ku, Pam M.

AU - Waller, Jennifer L

AU - Sportes, Claude

AU - Clemmons, Amber B.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Purpose: Hematopoietic cell transplant (HCT) recipients often require intravenous (IV) magnesium repletion due to poor dietary intake, gastrointestinal loss, and use of concomitant magnesium wasting medications. Prolonging the IV magnesium infusion rate has been postulated to reduce renal clearance and improve retention; however, limited evidence supports this hypothesis. Methods: We reviewed autologous and allogeneic HCT recipients (n = 82) who received IV magnesium at our institution between 2014 and 2016: 41 patients received IV magnesium at a prolonged rate of 0.5 g/h and 41 patients at > 0.5 g/h (mean 2.07 g/h). Primary outcome was percent of days in which magnesium levels were in desired therapeutic range (2–2.7 mg/dL) during hospitalization. Results: Baseline characteristics were similar between cohorts: no difference existed between groups in incidence of gastrointestinal graft-versus-host disease or the percentage of patients who received magnesium replacement in maintenance fluids, received concomitant oral magnesium supplementation, or received parenteral nutrition. Percent of days in desired therapeutic range was not different between groups (p = 0.3). No difference existed between groups with respect to total amount of IV magnesium repletion (22.5 vs. 21.4 g, p = 0.81) or number of days of IV replacement (7.2 vs. 6.2 days, p = 0.41). In terms of safety, there was no difference between groups with respect to incidence of hypomagnesemia or hypermagnesemia (p = 0.43 each). Conclusions: Overall, prolonging the infusion rate did not correlate with improved magnesium retention based on amount and frequency of magnesium repletion or attainment of goal levels in HCT patients.

AB - Purpose: Hematopoietic cell transplant (HCT) recipients often require intravenous (IV) magnesium repletion due to poor dietary intake, gastrointestinal loss, and use of concomitant magnesium wasting medications. Prolonging the IV magnesium infusion rate has been postulated to reduce renal clearance and improve retention; however, limited evidence supports this hypothesis. Methods: We reviewed autologous and allogeneic HCT recipients (n = 82) who received IV magnesium at our institution between 2014 and 2016: 41 patients received IV magnesium at a prolonged rate of 0.5 g/h and 41 patients at > 0.5 g/h (mean 2.07 g/h). Primary outcome was percent of days in which magnesium levels were in desired therapeutic range (2–2.7 mg/dL) during hospitalization. Results: Baseline characteristics were similar between cohorts: no difference existed between groups in incidence of gastrointestinal graft-versus-host disease or the percentage of patients who received magnesium replacement in maintenance fluids, received concomitant oral magnesium supplementation, or received parenteral nutrition. Percent of days in desired therapeutic range was not different between groups (p = 0.3). No difference existed between groups with respect to total amount of IV magnesium repletion (22.5 vs. 21.4 g, p = 0.81) or number of days of IV replacement (7.2 vs. 6.2 days, p = 0.41). In terms of safety, there was no difference between groups with respect to incidence of hypomagnesemia or hypermagnesemia (p = 0.43 each). Conclusions: Overall, prolonging the infusion rate did not correlate with improved magnesium retention based on amount and frequency of magnesium repletion or attainment of goal levels in HCT patients.

KW - Administration

KW - Hematopoietic cell transplantation

KW - Intravenous

KW - Magnesium

KW - Rate

UR - http://www.scopus.com/inward/record.url?scp=85045075771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045075771&partnerID=8YFLogxK

U2 - 10.1007/s00520-018-4127-z

DO - 10.1007/s00520-018-4127-z

M3 - Article

C2 - 29508140

AN - SCOPUS:85045075771

VL - 26

SP - 2809

EP - 2814

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 8

ER -